Durata Therapeutics to Announce Second Quarter 2013 Financial Results on August 7, 2013

Durata Therapeutics, Inc. Logo

CHICAGO, July 31, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Wednesday, August 7th at 8:30 a.m. Eastern Time to discuss second quarter 2013 financial results.

The conference call will be available via phone and webcast. To access the call, please dial 866-632-4021 for participants in the U.S. or Canada and 404-991-3968 for international callers (reference Conference ID 12148199). A replay of the call may be accessed through August 21, 2013 by dialing 800-585-8367 for callers in the U.S. and Canada and 404-537-3406 for international callers (reference Conference ID 12148199). The conference call will also be webcast live on the Investor Relations section of the Company's website at www.duratatherapeutics.com.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed its DISCOVER 1 and DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.

CONTACT: Investor Relations and Public Affairs Contact Allison Wey - Durata Therapeutics Vice President, Investor Relations and Public Affairs (312)219-7017 - awey@duratatherapeutics.com

Source:Durata Therapeutics, Inc.